Gordon Winter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1847522/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting. PLoS ONE, 2022, 17, e0266906.	2.5	7
2	Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. Zeitschrift Fur Medizinische Physik, 2021, 31, 37-47.	1.5	1
3	A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	1.0	2
4	Comparison of Quantification of Target-Specific Accumulation of [18F]F-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI. Cancers, 2021, 13, 4007.	3.7	10
5	A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice. Pharmaceutics, 2021, 13, 2132.	4.5	9
6	Multi-Modal PET and MR Imaging in the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial In Vivo Testing of Target-Specific Radioligands. Cancers, 2020, 12, 1248.	3.7	18
7	In vivo PET/MRI Imaging of the Chorioallantoic Membrane. Frontiers in Physics, 2020, 8, .	2.1	14
8	Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands. Nuclear Medicine and Biology, 2019, 72-73, 20-25.	0.6	6
9	Quantitative and correlative biodistribution analysis of ⁸⁹ Zr-labeled mesoporous silica nanoparticles intravenously injected into tumor-bearing mice. Nanoscale, 2017, 9, 9743-9753.	5.6	35
10	Radiofluorination of PSMA-HBED via Al18F2+ Chelation and Biological Evaluations In Vitro. Molecular Imaging and Biology, 2015, 17, 777-785.	2.6	44
11	Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep. Pharmaceuticals, 2014, 7, 517-529.	3.8	29
12	Synthesis, characterization, and biodistribution of multiple ⁸⁹ Zr-labeled pore-expanded mesoporous silica nanoparticles for PET. Nanoscale, 2014, 6, 4928-4935.	5.6	69
13	Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 969-970.	6.4	16
14	A Universal Scaffold for Synthesis of the Fe(CN)2(CO) Moiety of [NiFe] Hydrogenase. Journal of Biological Chemistry, 2012, 287, 38845-38853.	3.4	49
15	Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep). Applied Radiation and Isotopes, 2011, 69, 1014-1018.	1.5	28
16	Crystallization and preliminary X-ray crystallographic analysis of the [NiFe]-hydrogenase maturation factor HypF1 from <i>Ralstonia eutropha</i> H16. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 452-455.	0.7	6
17	A model system for [NiFe] hydrogenase maturation studies: Purification of an active site-containing hydrogenase large subunit without small subunit. FEBS Letters, 2005, 579, 4292-4296.	2.8	38
18	The role of the active site-coordinating cysteine residues in the maturation of the H2-sensing [NiFe] hydrogenase from Ralstonia eutropha H16. Archives of Microbiology, 2004, 182, 138-46.	2.2	8